Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
AC Immune’s stock fell 9 percent on the news that the company’s Phase II Lauriet study of the investigational anti-Tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer’s disease (AD) did not meet all endpoints.
A new study suggests that some patients could see a decline in cognition that is equivalent to the brain aging approximately 10 years.
An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
A study of more than a thousand former professional soccer players has uncovered significantly more deaths from brain disease than among non-players.
Hearing loss in middle age is associated with higher odds of cognitive decline and dementia in later years, suggests a large study in Taiwan.
Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.
Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.
Learning new things, eating and drinking well, not smoking and limiting hearing loss and loneliness could prevent a third of dementia cases, health experts said.
(Reuters Health) – Seniors with hearing loss who use hearing aids may experience cognitive decline at a rate more like their peers without hearing trouble, according to a French study […]